查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1803122

萎缩性阴道炎治疗市场预测（至 2032 年）：按产品、患者细分、治疗类型、分销管道、最终用户和地区进行的全球分析

Atrophic Vaginitis Treatment Market Forecasts to 2032 - Global Analysis By Product, Patient Demographics, Treatment Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球萎缩性阴道炎治疗市场预计在 2025 年价值 16 亿美元，到 2032 年将达到 31 亿美元，预测期内的复合年增长率为 9.6%。

萎缩性阴道炎治疗是指旨在缓解其症状的治疗性介入。萎缩性阴道炎是一种以阴道壁变薄、干燥和发炎为特征的疾病，通常是由于停经后雌激素水平下降所致。治疗的重点是恢復阴道湿润度、弹性和pH值平衡，并缓解性交过程中的不适、搔痒、灼热和疼痛。常见的治疗方法包括局部或全身雌激素治疗、非荷尔蒙保湿剂和润滑剂，以及生活方式的改变，例如规律的性生活和骨盆底运动。

人口老化和更年期症状的日益普遍

随着预期寿命的延长，越来越多的女性进入停经后，阴道萎缩也随之增加。人们对更年期健康的认识日益提高，促使女性寻求医疗解决方案来缓解不适并改善生活品质。医疗保健提供者提供针对性的治疗方案，推动了更年期相关症状的广泛应用。更年期相关症状的普遍存在，使得对有效且安全的治疗方案的需求持续增长。总体而言，人口结构变化和日益增强的健康意识正在稳步推动市场成长。

社会耻辱与尴尬

女性常常不愿与医护人员讨论私密健康议题。这种不适感会导致诊断和治疗的延误。社会禁忌限制了人们对疾病的认识，并降低了患者的治疗需求。耻辱感和羞耻感降低了行销和教育工作的有效性。不愿就医直接影响了治疗方法的接受度。因此，萎缩性阴道炎治疗的市场成长仍然有限。

提高认识和教育

女性越来越意识到萎缩性阴道炎的症状和长期影响，鼓励她们及时就医。健康宣传活动和教育计画强调了治疗的重要性，并减少了讨论阴道健康相关的耻辱感。知识的增加使得人们更容易接受现有的治疗方法，包括荷尔蒙疗法和非荷尔蒙疗法。线上资源和远端医疗平台使资讯更容易获取，并增强了患者寻求治疗的能力。整体而言，更好的认识和教育直接增加了对有效萎缩性阴道炎治疗的需求。

来自替代疗法的竞争

自然疗法和草药补充剂在寻求更少副作用的患者中越来越受欢迎。这些替代疗法通常对那些偏好整体疗法和非药物疗法的消费者更具吸引力。非处方药的选择也减少了对处方笺药的依赖。多样化的治疗方案分散了市场占有率，并减缓了传统治疗方法的成长。因此，製药公司在患者保留和市场扩张方面面临挑战。

COVID-19的影响

新冠疫情扰乱了萎缩性阴道炎治疗市场，限制了患者就诊，并延误了常规妇科护理。供应链中断影响了治疗和药物的可近性。新冠疫情导致医疗资源投入增加，导致萎缩性阴道炎等慢性疾病的关注度下降。虽然远端医疗的普及在一定程度上缓解了治疗延误，但对于不熟悉数位平台的老年患者来说，障碍依然存在。此外，经济不确定性影响了消费者对非紧急治疗的支出意愿。总体而言，市场成长暂时放缓，但随着医疗服务可近性的恢復，预计将逐步恢復。

预计在预测期内，乳膏和药膏市场将占最大份额

预计乳膏和软膏类产品将在预测期内占据最大的市场占有率，因为它们可以直接缓解阴道干燥和刺激，提高患者的舒适度。便捷的使用方式有助于持续使用，并提高治疗顺从性。种类繁多的雌激素和非雌激素配方为患者提供了更多选择。良好的治疗效果可增强患者的信心并促进需求成长。总体而言，该类产品将透过有效缓解核心症状来推动市场成长。

预计在预测期内，自我药疗患者群体的复合年增长率最高。

预计在预测期内，自我药疗患者群体将实现最高成长率，这得益于对可及治疗需求的不断增长。他们积极主动的策略加速了产品的采用和市场渗透。外用乳霜、凝胶和阴道保湿剂的普及，促使人们频繁使用。製药公司正瞄准这群人，进行宣传宣传活动，并采用用户友好的包装。总体而言，自我治疗患者正在为市场基础的稳定成长和扩张做出贡献。

占比最大的地区：

在预测期内，北美预计将占据最大的市场占有率，这得益于其先进的医疗体系和广泛的保险覆盖。患者的高度认知和积极主动的妇科护理正在推动对有效治疗方法的需求。包括非荷尔蒙疗法在内的创新产品的推出正在塑造治疗偏好。人口老化趋势日益普遍，支持市场成长。老牌製药公司的强大存在确保了研发和分销的效率。数位健康工具和远端医疗正在改善患者的就医机会和依从性。然而，对监管审查和治疗成本的担忧可能会影响采用模式和市场动态。

复合年增长率最高的地区：

预计亚太地区将在预测期内实现最高的复合年增长率，这得益于女性健康意识的提升和医疗基础设施的完善。文化变革鼓励更多女性寻求治疗，而现代治疗方法的普及也推动了相关产品的采用。自我护理产品在新兴经济体中日益流行，製药公司也正在投资针对特定区域的配方。都市化和网路的普及正在推动病患教育，并提升市场渗透率。然而，农村地区的社会污名化仍然是阻碍治疗接受和应用的一大挑战。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球萎缩性阴道炎治疗市场（按产品）

  • 乳膏和药膏
  • 栓剂
  • 片剂和胶囊
  • 阴道环
  • 经皮吸收贴片
  • 其他产品

6. 全球萎缩性阴道炎治疗市场（依患者细分）

  • 停经后妇女
  • 围绝经期妇女
  • 接受过手术闭经的女性

7. 全球萎缩性阴道炎治疗市场（依治疗类型）

  • 荷尔蒙疗法
    • 雌激素治疗
    • 生物荷尔蒙疗法
  • 非荷尔蒙疗法
    • 阴道保湿剂
    • 水性润滑剂
    • 草药和天然疗法

8. 全球萎缩性阴道炎治疗市场（按分销管道）

  • 医院药房
  • 零售药局
  • 网路药局

9. 全球萎缩性阴道炎治疗市场（依最终用户）

  • 妇科医生
  • 全科医生
  • 病人
  • 其他最终用户

第十章全球萎缩性阴道炎治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Pfizer Inc.
  • Bayer AG
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Organon & Co.
  • Mylan NV
  • Endo International plc
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Lupin Limited
  • Cipla Ltd.
  • Astellas Pharma Inc.
  • Sanofi SA
  • Novartis AG
Product Code: SMRC30647

According to Stratistics MRC, the Global Atrophic Vaginitis Treatment Market is accounted for $1.6 billion in 2025 and is expected to reach $3.1 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Atrophic vaginitis treatment refers to medical and therapeutic interventions aimed at relieving the symptoms of atrophic vaginitis, a condition characterized by thinning, drying, and inflammation of the vaginal walls, typically due to decreased estrogen levels during menopause or post menopause. Treatments focus on restoring vaginal moisture, elasticity, and pH balance, while alleviating discomfort, itching, burning, and pain during intercourse. Common approaches include local or systemic estrogenic therapy, non-hormonal moisturizers and lubricants, and lifestyle modifications such as regular sexual activity or pelvic floor exercises.

Market Dynamics:

Driver:

Aging population and increased menopause prevalence

Longer life expectancy leads to more women living through post menopause, where vaginal atrophy is more prevalent. Increased awareness about menopausal health encourages women to seek medical solutions for discomfort and quality-of-life improvement. Healthcare providers are offering targeted therapies, boosting treatment adoption. The growing prevalence of menopause-related symptoms creates consistent demand for effective and safe treatment options. Overall, demographic shifts and heightened health consciousness propel market growth steadily.

Restraint:

Social stigma and embarrassment

Women often experience discomfort discussing intimate health issues with healthcare providers. Such discomfort causes delayed diagnosis and treatment. Societal taboos limit awareness, reducing patient demand for therapies. Stigma and embarrassment make marketing and educational efforts less effective. Reluctance to seek care directly impacts therapy adoption rates. Consequently, market growth for atrophic vaginitis treatments remains restricted.

Opportunity:

Growing awareness and education

Women are increasingly recognizing the symptoms and long-term effects of atrophic vaginitis, prompting timely medical consultations. Health campaigns and educational programs emphasize the importance of treatment, reducing stigma around discussing vaginal health. Increased knowledge leads to higher acceptance of available therapies, including hormonal and non-hormonal options. Online resources and telemedicine platforms make information more accessible, empowering patients to seek treatment. Overall, better awareness and education directly boost demand for effective atrophic vaginitis treatments.

Threat:

Competition from alternative therapies

Natural remedies and herbal supplements are gaining popularity among patients seeking fewer side effects. These alternatives often attract consumers who prefer holistic or non-pharmaceutical approaches. Over-the-counter options also reduce dependency on prescription treatments. The presence of diverse treatment choices divides the market share and slows growth for conventional therapies. As a result, pharmaceutical companies face challenges in patient retention and market expansion.

Covid-19 Impact

The Covid-19 pandemic disrupted the Atrophic Vaginitis Treatment Market by limiting patient visits and delaying routine gynaecological care. Supply chain interruptions affected the availability of treatments and medications. Heightened focus on healthcare resources for Covid-19 led to reduced attention on chronic conditions like atrophic vaginitis. Telemedicine adoption partially mitigated treatment delays, but barriers remained for older patients less familiar with digital platforms. Additionally, economic uncertainty impacted consumers' willingness to spend on non-urgent therapies. Overall, market growth slowed temporarily, with gradual recovery expected as healthcare access normalizes.

The creams & ointments segment is expected to be the largest during the forecast period

The creams & ointments segment is expected to account for the largest market share during the forecast period as they provide direct relief of vaginal dryness and irritation, improving patient comfort. Easy application encourages consistent use, boosting treatment adherence. Wide availability of estrogen and non-estrogen formulations expands patient options. Positive treatment outcomes increase patient trust and demand. Overall, this segment drives market growth by addressing core symptoms effectively.

The self-medicating patients' segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the self-medicating patients' segment is predicted to witness the highest growth rate, due to increasing demand for accessible treatments. Their proactive approach accelerates product adoption and market penetration. Easy availability of topical creams, gels, and vaginal moisturizers encourages frequent use. Pharmaceutical companies target this segment with awareness campaigns and user-friendly packaging. Overall, self-medicating patients contribute to steady growth and wider reach of the market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advanced healthcare systems and widespread insurance coverage. High patient awareness and proactive gynaecological care drive demand for effective therapies. Innovative product launches, including non-hormonal options, are shaping treatment preferences. Aging population trends increase prevalence, supporting market growth. Strong presence of established pharmaceutical companies ensures research, development, and distribution efficiency. Digital health tools and telemedicine are improving patient access and compliance. Nevertheless, regulatory scrutiny and treatment cost concerns can influence adoption patterns and market dynamics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to rising awareness of women's health and increasing healthcare infrastructure. Cultural shifts are encouraging more women to seek treatment, while the availability of modern therapies enhances adoption. Emerging economies are witnessing growth in self-care products, and pharmaceutical companies are investing in region-specific formulations. Urbanization and increased internet penetration facilitate patient education, boosting market penetration. However, social stigma in rural areas continues to pose challenges to treatment acceptance and outreach.

Key players in the market

Some of the key players profiled in the Atrophic Vaginitis Treatment Market include Pfizer Inc., Bayer AG, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Organon & Co., Mylan N.V., Endo International plc, Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Lupin Limited, Cipla Ltd., Astellas Pharma Inc., Sanofi S.A. and Novartis AG.

Key Developments:

In June 2024, Pfizer entered a strategic alliance with Flagship Pioneering to co-develop up to 10 single-asset drug programs. While not exclusively focused on atrophic vaginitis, the model is designed to accelerate R&D in areas including internal medicine and women's health.

In January 2024, Novo Holdings acquired CDMO Catalent for $16.5 billion. Three fill-finish sites will be transferred to Novo Nordisk for $11 billion. While the deal primarily supports GLP-1 production, it expands manufacturing capacity that could benefit hormone-based therapies like Vagifem(R).

Products Covered:

  • Creams & Ointments
  • Suppositories
  • Tablets & Capsules
  • Intravaginal Rings
  • Transdermal Patches
  • Other Products

Patient Demographics Covered:

  • Postmenopausal Women
  • Perimenopausal Women
  • Women with Surgical Menopause

Treatment Types Covered:

  • Hormonal Treatments
  • Non-Hormonal Treatments

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Gynaecologists
  • General Practitioners
  • Patients
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atrophic Vaginitis Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Creams & Ointments
  • 5.3 Suppositories
  • 5.4 Tablets & Capsules
  • 5.5 Intravaginal Rings
  • 5.6 Transdermal Patches
  • 5.7 Other Products

6 Global Atrophic Vaginitis Treatment Market, By Patient Demographics

  • 6.1 Introduction
  • 6.2 Postmenopausal Women
  • 6.3 Perimenopausal Women
  • 6.4 Women with Surgical Menopause

7 Global Atrophic Vaginitis Treatment Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Hormonal Treatments
    • 7.2.1 Estrogen Therapy
    • 7.2.2 Bioidentical Hormone Therapy
  • 7.3 Non-Hormonal Treatments
    • 7.3.1 Vaginal Moisturizers
    • 7.3.2 Water-Based Lubricants
    • 7.3.3 Herbal & Natural Remedies

8 Global Atrophic Vaginitis Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Atrophic Vaginitis Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Gynecologists
  • 9.3 General Practitioners
  • 9.4 Patients
  • 9.5 Other End Users

10 Global Atrophic Vaginitis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Bayer AG
  • 12.3 Novo Nordisk A/S
  • 12.4 Teva Pharmaceutical Industries Ltd.
  • 12.5 AbbVie Inc.
  • 12.6 Merck & Co., Inc.
  • 12.7 Amgen Inc.
  • 12.8 Eli Lilly and Company
  • 12.9 Organon & Co.
  • 12.10 Mylan N.V.
  • 12.11 Endo International plc
  • 12.12 Ferring Pharmaceuticals
  • 12.13 Glenmark Pharmaceuticals
  • 12.14 Lupin Limited
  • 12.15 Cipla Ltd.
  • 12.16 Astellas Pharma Inc.
  • 12.17 Sanofi S.A.
  • 12.18 Novartis AG

List of Tables

  • Table 1 Global Atrophic Vaginitis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Atrophic Vaginitis Treatment Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Atrophic Vaginitis Treatment Market Outlook, By Creams & Ointments (2024-2032) ($MN)
  • Table 4 Global Atrophic Vaginitis Treatment Market Outlook, By Suppositories (2024-2032) ($MN)
  • Table 5 Global Atrophic Vaginitis Treatment Market Outlook, By Tablets & Capsules (2024-2032) ($MN)
  • Table 6 Global Atrophic Vaginitis Treatment Market Outlook, By Intravaginal Rings (2024-2032) ($MN)
  • Table 7 Global Atrophic Vaginitis Treatment Market Outlook, By Transdermal Patches (2024-2032) ($MN)
  • Table 8 Global Atrophic Vaginitis Treatment Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 9 Global Atrophic Vaginitis Treatment Market Outlook, By Patient Demographics (2024-2032) ($MN)
  • Table 10 Global Atrophic Vaginitis Treatment Market Outlook, By Postmenopausal Women (2024-2032) ($MN)
  • Table 11 Global Atrophic Vaginitis Treatment Market Outlook, By Perimenopausal Women (2024-2032) ($MN)
  • Table 12 Global Atrophic Vaginitis Treatment Market Outlook, By Women with Surgical Menopause (2024-2032) ($MN)
  • Table 13 Global Atrophic Vaginitis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 14 Global Atrophic Vaginitis Treatment Market Outlook, By Hormonal Treatments (2024-2032) ($MN)
  • Table 15 Global Atrophic Vaginitis Treatment Market Outlook, By Estrogen Therapy (2024-2032) ($MN)
  • Table 16 Global Atrophic Vaginitis Treatment Market Outlook, By Bioidentical Hormone Therapy (2024-2032) ($MN)
  • Table 17 Global Atrophic Vaginitis Treatment Market Outlook, By Non-Hormonal Treatments (2024-2032) ($MN)
  • Table 18 Global Atrophic Vaginitis Treatment Market Outlook, By Vaginal Moisturizers (2024-2032) ($MN)
  • Table 19 Global Atrophic Vaginitis Treatment Market Outlook, By Water-Based Lubricants (2024-2032) ($MN)
  • Table 20 Global Atrophic Vaginitis Treatment Market Outlook, By Herbal & Natural Remedies (2024-2032) ($MN)
  • Table 21 Global Atrophic Vaginitis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Atrophic Vaginitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 23 Global Atrophic Vaginitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 24 Global Atrophic Vaginitis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 25 Global Atrophic Vaginitis Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Atrophic Vaginitis Treatment Market Outlook, By Gynecologists (2024-2032) ($MN)
  • Table 27 Global Atrophic Vaginitis Treatment Market Outlook, By General Practitioners (2024-2032) ($MN)
  • Table 28 Global Atrophic Vaginitis Treatment Market Outlook, By Patients (2024-2032) ($MN)
  • Table 29 Global Atrophic Vaginitis Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.